IP Library Granted Patent US 11,422,128
Granted Patent B2
US 11,422,128 · App. 16/092,684 · Granted Aug 23, 2022

Immunoassay employing sulfated polysaccharide

Inventors: Ryuhei Shimizu (Chiyoda-ku, JP); Keiichi Shoji (Chiyoda-ku, JP); Xu Zhang (Chiyoda-ku, JP)
Assignee: LSI MEDIENCE CORPORATION
G01N33/5306G01N33/48G01N33/53G01N33/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,422,128
App. No.
16/092,684
Granted
Aug 23, 2022
Kind
B2
Abstract

Regardless of the type of specimen, such as a serum or heparinized plasma containing different anticoagulants, which are widely used in general, when a substance to be measured (for example, sIL-2R) in a biological sample is immunologically detected, a measuring method and a kit capable of stably obtaining with high accuracy, unaffected by interfering substances in the specimen, are provided. An immunocomplex between the substance to be measured and an antibody that specifically binds to the substance to be measured is formed in the presence of a sulfated polysaccharide. The kit comprises an antibody that specifically binds to the substance to be measured, and a buffer containing a sulfated polysaccharide.

Claims (8)

1. A method of immunologically measuring a substance to be measured in a biological sample, said method comprising:

providing a sample selected from the group consisting of a blood sample to which heparin is added as an anticoagulant, and a serum sample;

bringing the sample into contact with an antibody that specifically binds to the substance to be measured in the presence of 0.002% to 0.4% β-cyclodextrin sulfate to form an immunocomplex; and

analyzing the immunocomplex or a signal derived from the immunocomplex.

2. The method according to claim 1 , wherein β-cyclodextrin sulfate is contained in a solution for diluting specimen and/or an antibody solution.

3. The method according to claim 1 , wherein the said analyzing comprises the step of separation of bound and free (B/F) of the formed immunocomplex.

4. The method according to claim 1 , wherein the step of bringing the substance into contact with an antibody comprises contacting with a second antibody that specifically binds to the substance to be measured.

5. The method according to claim 1 , wherein the substance to be measured is soluble interleukin-2 receptor or prostate specific antigen.

Assignments (3)
CHANGE OF ADDRESS Recorded Feb 25, 2024
From: LSI MEDIENCE CORPORATION
To: LSI MEDIENCE CORPORATION
Reel/Frame 066674/0958 →
COMPANY SPLIT Recorded Feb 25, 2024
From: LSI MEDIENCE CORPORATION
To: PHC CORPORATION
Reel/Frame 066675/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: SHIMIZU, RYUHEI; SHOJI, KEIICHI; ZHANG, XU
To: LSI MEDIENCE CORPORATION
Reel/Frame 047131/0764 →
Priority Claims (1)
JP JP2016-080660 · Apr 13, 2016 · national
Continuity (1)
Related Publication 20190145965A1 · May 16, 2019